Leap Therapeutics Inc(LPTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LPTX Leap Therapeutics Inc

Trading 04-23 13:35:30 EDT

0.3913

+0.0053

+1.37%

High0.4000	Low0.3720	Vol333.42K
Open0.3720	D1 Closing0.3860	Amplitude7.25%
Mkt Cap16.14M	Tradable Cap12.44M	Total Shares41.26M
T/O130.23K	T/O Rate1.05%	Tradable Shares31.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LPTX","market":"US","secType":"STK","nameCN":"Leap Therapeutics Inc","latestPrice":0.3913,"timestamp":1745429522314,"preClose":0.386,"halted":0,"volume":333419,"delay":0,"floatShares":31782966,"shares":41257602,"eps":-1.811498,"marketStatus":"Trading","change":0.0053,"latestTime":"04-23 13:35:30 EDT","open":0.372,"high":0.4,"low":0.372,"amount":130226.37624624999,"amplitude":0.072539,"askPrice":0.3899,"askSize":600,"bidPrice":0.3898,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-1.811498,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.386,"preHourTrading":{"tag":"盘前","latestPrice":0.39,"preClose":0.386,"latestTime":"09:28 EDT","volume":8105,"amount":3042.5576714,"timestamp":1745414880159},"postHourTrading":{"tag":"盘后","latestPrice":0.3701,"preClose":0.386,"latestTime":"19:43 EDT","volume":1635,"amount":608.3379,"timestamp":1745365435178},"volumeRatio":1.761401,"impliedVol":2.2229,"impliedVolPercentile":0.92},"requestUrl":"/m/hq/s/LPTX/wiki","defaultTab":"wiki","newsList":[{"id":"2527492277","title":"Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492277","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492277?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ --Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key opinion leader  event featuring Zev A. Wainberg, MD, Professor of Medicine at University of California, Los Angeles  and co-director of the UCLA GI Oncology Program, on Wednesday, April 23, 2025 at 2:30 p.m. ET. To register, please click here.Dr. Wainberg will connect with Leap's Chief Medical Officer, Cynthia Sirard, MD, to discuss the unmet need and how sirexatamab  may improve upon the current treatment landscape for previously treated patients with advanced microsatellite stable  colorectal cancer .The event will focus on reviewing the positive data from Part B of the Phase 2 DeFianCe study of sirexatamab in second-line patients with advanced MSS CRC. Sirexatamab, Leap's most advanced clinical program, is a humanize","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","MSS","CRC","KOL","BK4213","BK4157","BK4563","BK4139","BK4505","AEIS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4181","BK4113","LENZ","BK4585","HST","LPTX","LU0456854461.SGD","LU0266512127.USD","BK4007","IE0031619046.USD","BK4588","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2522455332","title":"Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455332","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455332?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 01:29","pubTimestamp":1743010151,"startTime":"0","endTime":"0","summary":"Leap Therapeutics, Inc. presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab  in combination with bevacizumab and chemotherapy  compared to bevacizumab and chemotherapy .The trial enrolled patients with advanced microsatellite stable  colorectal cancer  who have received one prior systemic therapy for advanced disease.The updated analysis shared on Wednesday includes the overall response rate , an additional two months of patient follow-up for progression-free survival , and initial overall survival  data.As ofMarch 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.In patients with highDKK1levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm:. In patients who had not received prior anti-VEGF therapy, the sirexatamab Experimental Arm has a statistically significant 22%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-leap-therapeutics-unveils-172911695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4588","PFS","LENZ","ONC","BK4505","BK4609","IE00BMPRXQ63.HKD","BK4097","BK4113","BK4139","LU0348723411.USD","BK4585","IE00BMPRXR70.SGD","CRC","BK4543","LU0456854461.SGD","LU0266512127.USD","MSS","BK4195","OS","LPTX","BK4563","BK4141","IE00BMPRXN33.USD","ORR","BK4213"],"gpt_icon":1},{"id":"2522810870","title":"Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522810870","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522810870?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:31","pubTimestamp":1742992311,"startTime":"0","endTime":"0","summary":"Leap Therapeutics  said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.The company's shares were up more ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4563","LENZ","BK4505","LPTX"],"gpt_icon":1},{"id":"2522787346","title":"BRIEF-Leap Therapeutics Reports Fourth Quarter And FY 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522787346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522787346?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:18","pubTimestamp":1742987911,"startTime":"0","endTime":"0","summary":"BRIEF-Leap Therapeutics Reports Fourth Quarter And FY 2024 ResultsMarch 26 (Reuters) - Leap Therapeutics Inc LPTX.O:LEAP THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSSource text: ID:nPnbxNkGMaFurther company coverage: LPTX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA9KNBQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","LPTX","BK4505","BK4139"],"gpt_icon":0},{"id":"2522000820","title":"Leap Therapeutics Q4 Operating Expenses USD 16.125 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522000820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522000820?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:05","pubTimestamp":1742987103,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nPLX428874:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","LPTX","BK4139","BK4563"],"gpt_icon":0},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4113","LPTX","LU0348723411.USD","BK4097","IE00BMPRXN33.USD","CRC","ORR","BK4213","BK4141","BK4585","PFS","BK4609","BK4195","IE00BMPRXQ63.HKD","LENZ","IE00BMPRXR70.SGD","BK4563","BK4505","BK4588","LU0266512127.USD","LU0456854461.SGD","BK4139","BK4211","OS","MSS","BK4543"],"gpt_icon":1},{"id":"2522472820","title":"Leap Therapeutics Reports Positive Updated Data From Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522472820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522472820?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA852XK6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","BK4563","LPTX"],"gpt_icon":0},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LPTX","BK4211","BK4543","MSS","IE00BMPRXQ63.HKD","CRC","ARM","BK4588","IE00BMPRXR70.SGD","ORR","BK4609","BK4195","BK4213","BK4563","IE00BMPRXN33.USD","BK4097","LU0266512127.USD","LU0348723411.USD","BK4585","BK4141","BK4113","LENZ","LU0456854461.SGD","PFS","BK4505","OS","BK4139"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXC","IKT","KBH","SCS","LPTX","SDST","KOD","MKC","DLTR","IOBT","WOOF","THRD","MDAI","SLRN","ABL","CTAS","BCAB","SURG","RLMD","MLKN","PAYX","CALC","UNCY","WGO","BEEM","PDSB","ZURA","ACRV","ALUR","ANTX","FBIO","CHWY","GOVX","DERM","PAYS","XFOR","EDAP","NUTX","AFMD","CDLR","GRDN","OBIO","MREO","WBA","SKYX","CRMD","RVPH","CLSD","TEN","IVA"],"gpt_icon":0},{"id":"2521894972","title":"Leap Therapeutics Inc  expected to post a loss of 38 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521894972","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521894972?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:01","pubTimestamp":1742562068,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc  expected to post a loss of38cents a share - Earnings Preview Leap Therapeutics Inc LPTX.OQ LPTX.O is expected to show no change in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q414W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LPTX"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRAG","MBRX","BCAB","COYA","CMC","RUM","WOR","CELC","FLUX","GDEV","LVTX","ASO","NKTX","BLRX","DERM","MNSO","RLMD","LPTX","OUST","SKYE","SBS","BBNX","LEN","BRNS","ACRV","CDLR","KLC","PAYX","DRI","TITN","NKE","SLS","MLKN","THRD","TH","SPRY","IFRX","CBUS","MGNX","MREO","FBRX","PL","SOWG","TELA","ALUR","JKS","CURV","JEF"],"gpt_icon":1},{"id":"2519527801","title":"Leap Therapeutics Inc  expected to post a loss of 38 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519527801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519527801?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 21:01","pubTimestamp":1741957264,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc  expected to post a loss of38cents a share - Earnings Preview Leap Therapeutics Inc LPTX.OQ LPTX.O is expected to show no change in quarterly revenue when it reports  results on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX16H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LPTX"],"gpt_icon":0},{"id":"2507270657","title":"Leap Therapeutics Shares Tumble After Downgrades from Baird, HC Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2507270657","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507270657?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 03:58","pubTimestamp":1738180681,"startTime":"0","endTime":"0","summary":"Leap Therapeutics  shares were down nearly 13% in recent trading Wednesday after Baird and HC Wainwright downgraded the stock to neutral.Baird also trimmed its price target to $1.25 from $9. The stock was previously rated outperform at Baird and buy at HC Wainwright.Almost 3 million shares traded so far, compared with a daily average of about 612,000.Price: 0.57, Change: -0.08, Percent Change: -12.92","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LPTX"],"gpt_icon":0},{"id":"2507687185","title":"Baird Downgrades Leap Therapeutics to Neutral From Outperform, Cuts Price Target to $1.25 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2507687185","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507687185?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 20:16","pubTimestamp":1738153010,"startTime":"0","endTime":"0","summary":"Baird Downgrades Leap Therapeutics to Neutral From Outperform, Cuts Price Target to $1.25 From $9","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LPTX"],"gpt_icon":0},{"id":"2507186687","title":"HC Wainwright Downgrades Leap Therapeutics to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507186687","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507186687?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 20:16","pubTimestamp":1738152997,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades Leap Therapeutics to Neutral From Buy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LPTX","LENZ"],"gpt_icon":0},{"id":"2507687545","title":"Leap Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507687545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507687545?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 20:04","pubTimestamp":1738152240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LPTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2025 07:04 ET (12:04 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LPTX"],"gpt_icon":0},{"id":"2507681510","title":"Leap Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507681510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507681510?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 19:06","pubTimestamp":1738148775,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nAZN38K7GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LPTX","BK4563","BK4505","BK4139"],"gpt_icon":0},{"id":"2507090185","title":"U.S. RESEARCH ROUNDUP-Apple, Coinbase Global, Nextracker","url":"https://stock-news.laohu8.com/highlight/detail?id=2507090185","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507090185?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 14:30","pubTimestamp":1738132221,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apple, Coinbase Global, Nextracker Jan 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apple, Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nL3N3OP0CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995401.HKD","LU2506951875.HKD","BK4008","BK4516","FIZN","LU1974910355.USD","RTX","LU2506952097.USD","HLI","OKUR","LRN","LPTX","NOW","PII","BK4581","JBLU","LU2506951792.HKD","LU2517655374.HKD","BK4596","LU2023250504.SGD","NVR","LU1244550577.SGD","HBCP","LU2362540622.SGD","SYK","LU2294711713.HKD","FCNCA","LU2517655291.USD","LU2552382215.SGD","LU0320765059.SGD","EL","LU2089984988.USD","FFIV","LU1430594728.SGD","BK4023","NXT","LU0823417653.USD","LU1280957306.USD","LU1366192091.USD","NUE","LU1978683503.SGD","GB00B4LPDJ14.GBP","LU0724618433.USD","MSBI","KMB","LU0690374961.EUR","KOPN","BK4190","MANH"],"gpt_icon":1},{"id":"2507088135","title":"Leap Therapeutics Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $1.25 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2507088135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507088135?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 12:15","pubTimestamp":1738124158,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OO1RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LPTX","BK4505","BK4139","BK4563"],"gpt_icon":0},{"id":"2507054216","title":"Gold Gains 1%; Boeing Shares Rise Following Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2507054216","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507054216?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 02:46","pubTimestamp":1738089998,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/43282917/gold-gains-1-boeing-shares-rise-following-q4-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","BK4161","BHF","PSQ","TQQQ","BK4162","BK4551","LU1435385759.SGD","SLXN","BA","LU2326559502.SGD","BK4505","MNQmain","USJW.SI","BK4516","QID","SQQQ","BK4187","BK4139","NQmain","TSYW.SI","BK4198","USAW.SI","BK4564","CR","BK4588","STSS","SABS",".IXIC","LPTX","NVIW.SI","LU1429558221.USD","BK4585","BK4563"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.leaptx.com","stockEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":-0.0374},{"period":"3month","weight":-0.8322},{"period":"6month","weight":-0.8827},{"period":"1year","weight":-0.8798},{"period":"ytd","weight":-0.8657}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.027306},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.021879},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.077902},{"month":4,"riseRate":0.444444,"avgChangeRate":0.012376},{"month":5,"riseRate":0.375,"avgChangeRate":0.13368},{"month":6,"riseRate":0.375,"avgChangeRate":-0.085816},{"month":7,"riseRate":0.25,"avgChangeRate":-0.025022},{"month":8,"riseRate":0.375,"avgChangeRate":0.017716},{"month":9,"riseRate":0.375,"avgChangeRate":0.051087},{"month":10,"riseRate":0.375,"avgChangeRate":-0.027895},{"month":11,"riseRate":0.25,"avgChangeRate":-0.083965},{"month":12,"riseRate":0.5,"avgChangeRate":0.157619}],"exchange":"NASDAQ","name":"Leap Therapeutics Inc","nameEN":"Leap Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Leap Therapeutics Inc(LPTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Leap Therapeutics Inc(LPTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Leap Therapeutics Inc,LPTX,Leap Therapeutics Inc股票,Leap Therapeutics Inc股票老虎,Leap Therapeutics Inc股票老虎国际,Leap Therapeutics Inc行情,Leap Therapeutics Inc股票行情,Leap Therapeutics Inc股价,Leap Therapeutics Inc股市,Leap Therapeutics Inc股票价格,Leap Therapeutics Inc股票交易,Leap Therapeutics Inc股票购买,Leap Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Leap Therapeutics Inc(LPTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Leap Therapeutics Inc(LPTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction